Quintiles and Allscripts have partnered to jointly develop software solutions for clinical and post-approval research.
The collaboration focuses on late-phase research, recruiting for and monitoring of clinical trials, and post-market surveillance.
The partnership aims at developing products that overcome obstructions in clinical research, outcomes, education and proof of new compound safety, effectiveness and value.
Quintiles R&D Innovation, IT, vice president Gavin Nichols said, “We believe biopharma, patients, providers and payers all will benefit from the technology solutions that grow from this undertaking.”
The new solution will enable customers to leverage de-identified longitudinal data, which could enable companies to improve the efficiency of processes involved in the development and evaluation of new drugs, from many sources in a HIPAA-compliant manner.
